341 related articles for article (PubMed ID: 17614227)
1. Interactions between 3,4-methylenedioxymethamphetamine, methamphetamine, ketamine, and caffeine in human intestinal Caco-2 cells and in oral administration to rats.
Kuwayama K; Inoue H; Kanamori T; Tsujikawa K; Miyaguchi H; Iwata Y; Miyauchi S; Kamo N; Kishi T
Forensic Sci Int; 2007 Aug; 170(2-3):183-8. PubMed ID: 17614227
[TBL] [Abstract][Full Text] [Related]
2. Interaction of 3,4-methylenedioxymethamphetamine and methamphetamine during metabolism by in vitro human metabolic enzymes and in rats.
Kuwayama K; Tsujikawa K; Miyaguchi H; Kanamori T; Iwata YT; Inoue H
J Forensic Sci; 2012 Jul; 57(4):1008-13. PubMed ID: 22211929
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic interactions between MDMA and concomitants in MDMA tablets on extracellular dopamine and serotonin in the rat brain.
Ikeda R; Igari Y; Fuchigami Y; Wada M; Kuroda N; Nakashima K
Eur J Pharmacol; 2011 Jun; 660(2-3):318-25. PubMed ID: 21497593
[TBL] [Abstract][Full Text] [Related]
4. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
McNamara R; Kerans A; O'Neill B; Harkin A
Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
[TBL] [Abstract][Full Text] [Related]
5. MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats.
Clemens KJ; Cornish JL; Li KM; Hunt GE; McGregor IS
Neuropharmacology; 2005 Aug; 49(2):195-207. PubMed ID: 15993443
[TBL] [Abstract][Full Text] [Related]
6. Uptake of 3,4-methylenedioxymethamphetamine and its related compounds by a proton-coupled transport system in Caco-2 cells.
Kuwayama K; Inoue H; Kanamori T; Tsujikawa K; Miyaguchi H; Iwata Y; Miyauchi S; Kamo N; Kishi T
Biochim Biophys Acta; 2008 Jan; 1778(1):42-50. PubMed ID: 17936243
[TBL] [Abstract][Full Text] [Related]
7. Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug.
Camarasa J; Pubill D; Escubedo E
Brain Res; 2006 Sep; 1111(1):72-82. PubMed ID: 16889759
[TBL] [Abstract][Full Text] [Related]
8. Intravenous methamphetamine self-administration in rats: effects of intravenous or intraperitoneal MDMA co-administration.
Clemens KJ; Cornish JL; Hunt GE; McGregor IS
Pharmacol Biochem Behav; 2006 Oct; 85(2):454-63. PubMed ID: 17112571
[TBL] [Abstract][Full Text] [Related]
9. Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain.
Yuki F; Rie I; Miki K; Mitsuhiro W; Naotaka K; Kenichiro N
Eur J Pharm Sci; 2013 Apr; 49(1):57-64. PubMed ID: 23395913
[TBL] [Abstract][Full Text] [Related]
10. Caffeine induces a profound and persistent tachycardia in response to MDMA ("Ecstasy") administration.
McNamara R; Maginn M; Harkin A
Eur J Pharmacol; 2007 Jan; 555(2-3):194-8. PubMed ID: 17126829
[TBL] [Abstract][Full Text] [Related]
11. Chemical profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets seized in Hong Kong.
Cheng WC; Poon NL; Chan MF
J Forensic Sci; 2003 Nov; 48(6):1249-59. PubMed ID: 14640267
[TBL] [Abstract][Full Text] [Related]
12. Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats.
Clemens KJ; Cornish JL; Hunt GE; McGregor IS
Drug Alcohol Depend; 2007 Jan; 86(2-3):183-90. PubMed ID: 16884865
[TBL] [Abstract][Full Text] [Related]
13. An in vitro approach to assessing a potential drug interaction between MDMA (ecstasy) and caffeine.
Downey C; Daly F; O'Boyle KM
Toxicol In Vitro; 2014 Mar; 28(2):231-9. PubMed ID: 24211539
[TBL] [Abstract][Full Text] [Related]
14. Transport characteristics of zolmitriptan in a human intestinal epithelial cell line Caco-2.
Yu L; Zeng S
J Pharm Pharmacol; 2007 May; 59(5):655-60. PubMed ID: 17524230
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.
Mas M; Farré M; de la Torre R; Roset PN; Ortuño J; Segura J; Camí J
J Pharmacol Exp Ther; 1999 Jul; 290(1):136-45. PubMed ID: 10381769
[TBL] [Abstract][Full Text] [Related]
16. Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China.
Zhang Y; Lu C; Zhang J; Hu L; Song H; Li J; Kang L
Addict Behav; 2013 Jan; 38(1):1424-30. PubMed ID: 23006246
[TBL] [Abstract][Full Text] [Related]
17. The effects of co-administration of 3,4-methylenedioxymethamphetamine ("ecstasy") or para-methoxyamphetamine and moclobemide at elevated ambient temperatures on striatal 5-HT, body temperature and behavior in rats.
Stanley N; Salem A; Irvine RJ
Neuroscience; 2007 Apr; 146(1):321-9. PubMed ID: 17306465
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of hair roots for detection of methamphetamine and 3,4-methylenedioxymethamphetamine abuse by use of an HPLC-chemiluminescence method.
Wada M; Ochi Y; Nogami K; Ikeda R; Kuroda N; Nakashima K
Anal Bioanal Chem; 2012 Jul; 403(9):2569-76. PubMed ID: 22566199
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxicity mechanisms of thioether ecstasy metabolites.
Capela JP; Macedo C; Branco PS; Ferreira LM; Lobo AM; Fernandes E; Remião F; Bastos ML; Dirnagl U; Meisel A; Carvalho F
Neuroscience; 2007 Jun; 146(4):1743-57. PubMed ID: 17467183
[TBL] [Abstract][Full Text] [Related]
20. Examining the effect of dl-3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on the Standardized Field Sobriety Tests.
Downey LA; King R; Papafotiou K; Swann P; Ogden E; Stough C
Forensic Sci Int; 2012 Jul; 220(1-3):e33-6. PubMed ID: 22459201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
